A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Public ClinicalTrials.gov record NCT07227402. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)
Study identification
- NCT ID
- NCT07227402
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 904 participants
Conditions and interventions
Conditions
Interventions
- Belzutifan Drug
- Zanzalintinib Drug
- Cabozantinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 25, 2025
- Primary completion
- Feb 26, 2032
- Completion
- Feb 26, 2032
- Last update posted
- Jul 19, 2026
2025 – 2032
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Oncology and Hematology ( Site 0133) | Anchorage | Alaska | 99508 | Recruiting |
| Providence Medical Foundation ( Site 0141) | Fullerton | California | 92835 | Recruiting |
| New England Cancer Specialists ( Site 0132) | Westbrook | Maine | 04092 | Recruiting |
| Greater Baltimore Medical Center ( Site 0145) | Baltimore | Maryland | 21204 | Recruiting |
| Metro-Minnesota Community Clinical Oncology ( Site 0144) | Saint Louis Park | Minnesota | 55426 | Recruiting |
| Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0131) | Omaha | Nebraska | 68130-2042 | Recruiting |
| Carolina Oncology Specialists, PA ( Site 9002) | Charlotte | North Carolina | 28207 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 112 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07227402, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 19, 2026 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07227402 live on ClinicalTrials.gov.